LAVA Therapeutics N.V. Stock Price, News & Analysis

LAVA Therapeutics (Nasdaq: LVTX) announced encouraging results from preclinical data on its Gammabody™ platform, specifically for its lead solid tumor candidate, LAVA-1207, targeting metastatic castration-resistant prostate cancer (mCRPC). The bispecific antibody platform demonstrated potent anti-tumor activity while minimizing toxicity. Recruitment is underway for a Phase 1/2a trial to evaluate LAVA-1207's safety and efficacy. Non-human primate studies confirmed the safety and tolerability of its Gammabody™ technology, supporting its potential for enhanced therapeutic benefits.

LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced that CEO Stephen Hurly will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 1:30 p.m. EST. The company is focused on its Gammabody™ platform, which develops bispecific gamma delta T cell engagers for cancer treatment. Hurly expressed optimism about the company’s transformative journey in 2021 and its patient recruitment for Gammabody™ programs. Data from ongoing clinical studies is expected in 2022, with active recruitment for prostate cancer trials.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported financial results for Q3 2021, highlighting a cash position of €122.7 million as of September 30, 2021, a significant increase from €12.9 million at year-end 2020. The company's research and license revenue rose to €1.8 million for the quarter, attributed to its collaboration with Janssen Biotech. LAVA-051, undergoing a Phase 1/2a trial for hematological malignancies, received orphan drug designation from the FDA, while the LAVA-1207 trial for metastatic prostate cancer is set to begin soon. However, the net loss for Q3 2021 was €7.5 million, or €0.23 per share.

LAVA Therapeutics (Nasdaq: LVTX) announced a virtual symposium titled Emerging cancer therapies leveraging gamma-delta effector T cells scheduled for Nov. 29, 2021. Co-organized with The Antibody Society, the event features leading experts discussing advancements in cancer therapeutics using gamma-delta T cells. Notable speakers include Prof. Hans van der Vliet and Prof. James Allison. The symposium aims to explore the therapeutic potential of these T cells in oncology.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the expansion of its management team with three key appointments. Jessica Truscello joins as Vice President of Clinical Operations, bringing over 20 years of oncology expertise. Sumeet Ambarkhane, M.D. becomes the Executive Medical Director, leveraging his 17 years in oncology and hemato-oncology. Wouter van Hunnik is appointed Vice President of Human Resources, with over 15 years of HR leadership experience. These additions aim to enhance LAVA's capabilities as it transitions to a clinical-stage organization focused on developing bispecific gamma delta T cell engagers for cancer treatment.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will participate in a virtual fireside chat at the 12th Annual Jefferies London Healthcare Conference from Nov. 16-19, 2021. The chat will be available from 3:00 a.m. ET on Nov. 18 until 12:00 p.m. ET on Nov. 19. LAVA's leadership will also engage in one-on-one investor meetings during the event. Attendees can register for the conference and access the recording of the chat on LAVA's investor relations website.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that Paul W.H.I. Parren, Ph.D., its EVP and Head of R&D, will present data on bispecific gamma delta T cell engagers from their proprietary Gammabody™ platform at three upcoming scientific conferences in November 2021. The platform aims to revolutionize cancer treatment by combining effective tumor cell killing with low toxicity risks. Dr. Parren will chair sessions and participate in key discussions, including one on Nov. 3 at the Annual PEGS Europe Summit and another on Nov. 9 during the European Antibody Congress.

LAVA Therapeutics (Nasdaq: LVTX) announced that the FDA granted orphan drug designation for LAVA-051, a bispecific antibody targeting chronic lymphocytic leukemia (CLL). The designation will facilitate communication with the FDA and provide incentives for development, such as tax credits and potential market exclusivity. LAVA-051 is currently in a Phase 1/2a clinical trial for relapsed or refractory CLL, multiple myeloma, and acute myeloid leukemia, with preliminary data expected in 2022.